Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema

Acta Ophthalmologica

Volumn 93, Issue 7, 2015, Pages 610-615

  Ohira, Akihiro ^a   Hara, Katsunori ^a   Jóhannesson, Gauti ^b   Tanito, Masaki ^a   Ásgrímsdóttir, Gudrún Marta ^c   Lund, Sigrún H ^d   Loftsson, Thorsteinn ^d   Stefánsson, Einar ^e  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b UMEÅ UNIVERSITY   (Sweden)

^c Oculis Ehf   (Iceland)

^d UNIVERSITY OF ICELAND   (Iceland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

cyclodextrin; dexamethasone; diabetes macular edema; nanoparticle; topical treatment; triamcinolone

Indexed keywords

CORTICOTROPIN; DEXAMETHASONE; EYE DROPS; GAMMA CYCLODEXTRIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; NANOPARTICLE; TRIAMCINOLONE ACETONIDE; GAMMA CYCLODEXTRIN DERIVATIVE; GAMMA-CYCLODEXTRIN; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTRAOCULAR PRESSURE; MACULAR THICKNESS; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; COMPARATIVE STUDY; DIABETIC RETINOPATHY; DRUG EFFECTS; INTRAOCULAR DRUG ADMINISTRATION; MACULAR EDEMA; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; TENON CAPSULE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; DEXAMETHASONE; DIABETIC RETINOPATHY; FEMALE; GAMMA-CYCLODEXTRINS; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR EDEMA; MALE; MIDDLE AGED; NANOPARTICLES; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; RETINA; TENON CAPSULE; TOMOGRAPHY, OPTICAL COHERENCE; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 84945477033     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12803     Document Type: Article

References (24)

1. Bandello F, Casalino G, Loewenstein A, Goldstein M, Pelayes D, &, Battaglia Parodi M, (2014): Pharmacological approach to diabetic macular edema. Ophthalmic Res 51: 88-95.
2. Boyer DS, Faber D, Gupta S, et al., (2011): Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31: 915-923.
3. Callanan DG, Gupta S, Boyer DS, et al., (2013): Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema. Ophthalmology 120: 1843-1851.
4. Campochiaro PA, Brown DM, Pearson A, et al., (2012): Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119: 2125-2132.
5. Cho HY, Kang SW, Kim YT, Chung SE, &, Lee SW, (2012): A three-year follow-up of intravitreal triamcinolone acetonide injection and macular laser photocoagulation for diffuse diabetic macular edema. Korean J Ophthalmol 26: 362-368.
6. Ciulla TA, Harris A, McIntyre N, &, Jonescu-Cuypers C, (2014): Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant. Expert Opin Pharmacother 15: 953-959.
7. Diabetic Retinopathy Clinical Research Network, Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, Ferris FL III, Friedman SM, Glassman AR, Miller KM, Scott IU, Stockdale CR, &, Sun JK, (2010): Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064-1077 e1035.
8. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, &, Corcostegui B, (2014): Dexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edema. Ophthalmologica 231: 141-146.
9. Elman MJ, Bressler NM, Qin H, et al., & Diabetic Retinopathy Clinical Research N (2011): Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118: 609-614.
10. Fasce F, Battaglia Parodi M, Knutsson KA, Spinelli A, Mauceri P, Bolognesi G, &, Bandello F, (2014): Accidental injection of dexamethasone intravitreal implant in the crystalline lens. Acta Ophthalmol 92: e330-e331.
11. Information OP (2014): Highlight of prescribing information for ozurdex. In: Irvine, CA: Allergan Inc 1-11.
12. Jansook P, Ritthidej GC, Ueda H, Stefansson E, &, Loftsson T, (2010): yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. J Pharm Pharm Sci 13: 336-350.
13. Johannesson G, Moya-Ortega MD, Asgrimsdottir GM, Lund SH, Thorsteinsdottir M, Loftsson T, &, Stefansson E, (2013): Kinetics of gamma-cyclodextrin nanoparticle suspension eye drops in tear fluid. Acta Ophthalmol, 92: 550-556.
14. Kriechbaum K, Prager S, Mylonas G, Scholda C, Rainer G, Funk M, Kundi M, Schmidt-Erfurth U, & Diabetic Retinopathy Research G (2014): Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results. Eye 28: 9-15; quiz 16.
15. Loftsson T, Hreinsdottir D, &, Stefansson E, (2007): Cyclodextrin microparticles for drug delivery to the posterior segment of the eye: aqueous dexamethasone eye drops. J Pharm Pharmacol 59: 629-635.
16. Loftsson T, Sigurdsson HH, Konradsdottir F, Gisladottir S, Jansook P, &, Stefansson E, (2008): Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 63: 171-179.
17. Nakano S, Yamamoto T, Kirii E, Abe S, &, Yamashita H, (2010): Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 248: 805-810.
18. Ozdek S, Bahceci UA, Gurelik G, &, Hasanreisoglu B, (2006): Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema. J Diabetes Complications 20: 246-251.
19. Pacella E, Vestri AR, Muscella R, Carbotti MR, Castellucci M, Coi L, Turchetti P, &, Pacella F, (2013): Preliminary results of an intravitreal dexamethasone implant (Ozurdex(R)) in patients with persistent diabetic macular edema. Clin Ophthalmol 7: 1423-1428.
20. Sarao V, Veritti D, Boscia F, &, Lanzetta P, (2014): Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014: 989501.
21. Sigurdsson HH, Konraethsdottir F, Loftsson T, &, Stefansson E, (2007): Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 85: 598-602.
22. Simo R, Sundstrom JM, &, Antonetti DA, (2014): Ocular anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy. Diabetes Care 37: 893-899.
23. Tanito M, Hara K, Takai Y, et al., (2011): Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 52: 7944-7948.
24. Zucchiatti I, Lattanzio R, Querques G, Querques L, Del Turco C, Cascavilla ML, &, Bandello F, (2012): Intravitreal dexamethasone implant in patients with persistent diabetic macular edema. Ophthalmologica 228: 117-122.